INTRODUCTIONPrognosis prediction in RPS patientsRetroperitoneal sarcomas (RPS) are a heterogeneous group of tumors with a wide prognostic range. Contrary to other sarcoma sites such as the extremities where outcome is primarily limited by distant failure, local control is the central challenge in RPS patients. The main tumor‐related prognostic factors in RPS have historically been pathologic grade, size, histologic subtype, and multifocality. Also patient characteristics such as age at presentation and treatment variables such as completeness of resection, tumor rupture, and center expertise exert a strong influence on patient prognosis. The relative contribution of each prognostic factor on the oncological outcome is different and only considering the simultaneous effect of the combination of each variable can the physician attempt to define the clinical course of retroperitoneal sarcoma.Although the 10‐year overall survival (OS) of primary resected RPS patients is about 46% the natural history of these tumors varies widely according to the histological subtype. Specifically, more favorable histologies include well‐differentiated liposarcoma (WDLPS) and solitary fibrous tumor (SFT), as the 7‐year OS is greater than 80% in these subtypes. SFT are generally cured with adequate surgical resection, although a minority (less than 10%), have more aggressive behavior with metastatic potential. WDLPS in
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera